Kirsten Gillibrand on Bolstering US Domestic Medicine Manufacturing for Public Health

Vulnerable Generic Drug Supply Chain

• 💊 Many aging Americans, including over 53 million Medicare Part D enrollees, rely on generic drugs for various conditions.
• ⚠️ The current supply chain for these crucial drugs is vulnerable to disruptions, leading to shortages and quality issues with foreign-made products.
• 😔 Patients face worsening symptoms, skipped doses, and financial strain due to medication unavailability and affordability issues.

Factors Driving Supply Chain Disruptions

• 📉 The extreme cost pressures and concentrated sourcing have led to key starting materials, APIs, and finished generic drugs being manufactured outside the U.S.
• 📉 U.S. facilities formulating generic drugs have fallen by 27% since 2013, with a 38% decrease in domestic API-producing facilities.
• 📍 Currently, 83% of the top 100 generic drugs lack a U.S.-based API source, and 11% have only one domestic source.
• 🌍 Increased dependence on countries like India and China for upstream materials, compounded by geopolitical instability and trade practices, limits U.S. oversight.

Impact on Public Health and National Security

• 📉 The decline in U.S. manufacturing has resulted in job losses and created significant vulnerabilities in the drug supply chain.
• ⚠️ This poses a risk to the nation's public health preparedness and national security.

Proposed Solutions for Strengthening Supply

• 💰 Targeted investments in biotechnology research and infrastructure are needed to manufacture key ingredients domestically.
• ⚖️ Examining and adjusting underlying economic dynamics and incentives is crucial to address the "race to the bottom" in generic drug pricing.
• 🤝 Congress must work to strengthen the generic drug supply, bolster public health preparedness, and enhance national security.